Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
Temporary suspension of endocrine medication to seek pregnancy did not give a higher short-term risk of breast cancer events, including distant recurrence, than the external control cohort among select women with previous hormone receptor-positive (HR+) early breast cancer. Further investigation is required to ensure long-term safety.
Oncology, Medical May 8th 2023
OBR Oncology
The recent acquisition of OneOncology by AmerisourceBergen Corporation and TPG Capital highlights the potential for private equity to support and grow community oncology care across the United States. Private equity firms are seeing opportunities in oncology, as they could help slow or reverse the trend of hospitals consolidating practices by providing significant funding needed upfront to start and operate a community oncology practice. With all the changing insurance relationships and the cost of doing business on a day-to-day basis, that’s a pretty risky proposition. But if private equity firms provide capital support, then it’s somebody else’s financial risk. OneOncology is a management services organization that partners with community oncology practices to provide resources that help institutions improve care and remain sustainable as the reimbursement environment changes. Its services provide “shelter in the storm,” especially with value-based care. Many practices are entering into reimbursement models in which they are taking on downside-risk, being part of OneOncology’s network allows them to spread and minimize potential financial loss. The uniqueness of this model is that it supports practices while keeping the operational decision-making at the practice-level independent. The recent acquisition of OneOncology is further proof that OneOncology’s mission is receiving greater support, and […]
A total of 246 patients were randomly allocated to one of two groups: adult patients who had received no more than two previous chemotherapy regimens for the treatment of advanced colorectal cancer (combination group) or FTD-TPI alone (FTD-TPI group). The median overall survival in the combo group was 10.8 months and 7.5 months in the FTD-TPI group. The median progression-free survival in the combo group was 5.6 months and 2.4 months in the FTD-TPI group.
Guideline Central
Check out the updated guideline for changes prevention and treatment of VTE in a variety of cancer settings.
Family Medicine/General Practice May 3rd 2023
myCME
This educational program aims to improve the knowledge and comprehension of the clinical trial and real-world evidence for the CDK4/6i class among HCPs. A greater percentage of patients with HR+/HER2 metastatic breast cancer (mBC) will have access to this therapeutic option by filling care gaps linked to CDK4/6i usage. The course will largely center on three (3) core learning areas: best practices in CDK4/6i therapy management, the significance of real-world evidence (RWE) in treatment decision-making, and CDK4/6i in mBC: indications, clinical data, and RWE.
Oncology, Medical May 1st 2023
PracticeUpdate
Previously untreated patients in this phase III research receiving enzalutamide with or without abiraterone acetate and prednisone (AAP) were being treated for metastatic castration-resistant prostate cancer (mCRPC). Median overall survival (OS), the main outcome, did not differ statistically between the two groups. Enzalutamide plus AAP, however, resulted in a longer radiographic progression-free survival (rPFS) than enzalutamide alone. Abiraterone clearance was two to three times higher when administered with enzalutamide than when given alone, according to pharmacokinetic studies. In the combo arm, there were more high-grade adverse events, such as atrial fibrillation, transaminitis, hypertension, and fatigue. Patients with mCRPC did not have their OS lengthened by the addition of AAP to enzalutamide, and the authors theorize that this may have been due to the combination arm’s higher abiraterone clearance.